BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 10357408)

  • 1. Cisplatin in combination with irinotecan in the treatment of patients with malignant pleural mesothelioma: a pilot phase II clinical trial and pharmacokinetic profile.
    Nakano T; Chahinian AP; Shinjo M; Togawa N; Tonomura A; Miyake M; Ninomiya K; Yamamoto T; Higashino K
    Cancer; 1999 Jun; 85(11):2375-84. PubMed ID: 10357408
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Docetaxel and irinotecan (CPT-11) in the treatment of malignant pleural mesothelioma--a feasibility study.
    Knuuttila A; Ollikainen T; Halme M; Mali P; Kivisaari L; Linnainmaa K; Jekunen A; Mattson K
    Anticancer Drugs; 2000 Apr; 11(4):257-61. PubMed ID: 10898540
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relationship between the pharmacokinetics of irinotecan and diarrhea during combination chemotherapy with cisplatin.
    Kudoh S; Fukuoka M; Masuda N; Yoshikawa A; Kusunoki Y; Matsui K; Negoro S; Takifuji N; Nakagawa K; Hirashima T
    Jpn J Cancer Res; 1995 Apr; 86(4):406-13. PubMed ID: 7775263
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I study of irinotecan and cisplatin with granulocyte colony-stimulating factor support for advanced non-small-cell lung cancer.
    Masuda N; Fukuoka M; Kudoh S; Kusunoki Y; Matsui K; Nakagawa K; Hirashima T; Tamanoi M; Nitta T; Yana T
    J Clin Oncol; 1994 Jan; 12(1):90-6. PubMed ID: 7505810
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I clinical trial of irinotecan (CPT-11), 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxy-camptothecin, and cisplatin in combination with fixed dose of vindesine in advanced non-small cell lung cancer.
    Shinkai T; Arioka H; Kunikane H; Eguchi K; Sasaki Y; Tamura T; Ohe Y; Oshita F; Nishio M; Karato A
    Cancer Res; 1994 May; 54(10):2636-42. PubMed ID: 8168091
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I and pharmacokinetic study of irinotecan (CPT-11) administered daily for three consecutive days every three weeks in patients with advanced solid tumors.
    Catimel G; Chabot GG; Guastalla JP; Dumortier A; Cote C; Engel C; Gouyette A; Mathieu-Boué A; Mahjoubi M; Clavel M
    Ann Oncol; 1995 Feb; 6(2):133-40. PubMed ID: 7786821
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cisplatin and irinotecan (CPT-11) for peritoneal mesothelioma.
    Le DT; Deavers M; Hunt K; Malpica A; Verschraegen CF
    Cancer Invest; 2003; 21(5):682-9. PubMed ID: 14628425
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I and pharmacologic study of irinotecan in combination with cisplatin for advanced lung cancer.
    Masuda N; Fukuoka M; Kudoh S; Kusunoki Y; Matsui K; Takifuji N; Nakagawa K; Tamanoi M; Nitta T; Hirashima T
    Br J Cancer; 1993 Oct; 68(4):777-82. PubMed ID: 8398707
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dihydro-5-azacytidine and cisplatin in the treatment of malignant mesothelioma: a phase II study by the Cancer and Leukemia Group B.
    Samuels BL; Herndon JE; Harmon DC; Carey R; Aisner J; Corson JM; Suzuki Y; Green MR; Vogelzang NJ
    Cancer; 1998 Apr; 82(8):1578-84. PubMed ID: 9554537
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prospective study of combination chemotherapy with cyclophosphamide, doxorubicin, and cisplatin for unresectable or metastatic malignant pleural mesothelioma.
    Shin DM; Fossella FV; Umsawasdi T; Murphy WK; Chasen MH; Walsh G; Komaki R; McMurtrey MJ; Hong WK
    Cancer; 1995 Dec; 76(11):2230-6. PubMed ID: 8635025
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetic study of two infusion schedules of irinotecan combined with cisplatin in patients with advanced gastric cancer.
    Fujitani K; Tsujinaka T; Hirao M
    Oncology; 2003; 64(2):111-5. PubMed ID: 12566907
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thoracic stop-flow perfusion in the treatment of refractory malignant pleural mesothelioma: a phase I-II evaluation/trial.
    Guadagni S; Clementi M; Valenti M; Fiorentini G; Cantore M; Kanavos E; Amicucci G
    In Vivo; 2006; 20(6A):715-8. PubMed ID: 17203752
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I evaluation of sequential topoisomerase targeting with irinotecan/cisplatin followed by etoposide in patients with advanced malignancy.
    Licitra EJ; Vyas V; Nelson K; Musanti R; Beers S; Thomas C; Poplin E; Smith S; Lin Y; Schaaf LJ; Aisner J; Gounder M; Rajendra R; Saleem A; Toppmeyer D; Rubin EH
    Clin Cancer Res; 2003 May; 9(5):1673-9. PubMed ID: 12738720
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Irinotecan in combination with thalidomide in patients with advanced solid tumors: a clinical study with pharmacodynamic and pharmacokinetic evaluation.
    Allegrini G; Di Paolo A; Cerri E; Cupini S; Amatori F; Masi G; Danesi R; Marcucci L; Bocci G; Del Tacca M; Falcone A
    Cancer Chemother Pharmacol; 2006 Nov; 58(5):585-93. PubMed ID: 16680463
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Irinotecan (CPT-11) in combination with weekly administration of cisplatin (CDDP) for non-small-cell lung cancer.
    Kobayashi K; Shinbara A; Kamimura M; Takeda Y; Kudo K; Kabe J; Hibino S; Hino M; Shibuya M; Kudoh S
    Cancer Chemother Pharmacol; 1998; 42(1):53-8. PubMed ID: 9619758
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Results of a phase II trial of combined chemotherapy for patients with diffuse malignant mesothelioma of the pleura.
    Kasseyet S; Astoul P; Boutin C
    Cancer; 1999 Apr; 85(8):1740-9. PubMed ID: 10223568
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of pemetrexed in combination with cisplatin for malignant pleural mesothelioma: a phase I/II study in Japanese patients.
    Nakagawa K; Yamazaki K; Kunitoh H; Hida T; Gemba K; Shinkai T; Ichinose Y; Adachi S; Nambu Y; Saijo N; Fukuoka M
    Jpn J Clin Oncol; 2008 May; 38(5):339-46. PubMed ID: 18434338
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I clinical and pharmacologic study of weekly cisplatin combined with weekly irinotecan in patients with advanced solid tumors.
    Saltz LB; Spriggs D; Schaaf LJ; Schwartz GK; Ilson D; Kemeny N; Kanowitz J; Steger C; Eng M; Albanese P; Semple D; Hanover CK; Elfring GL; Miller LL; Kelsen D
    J Clin Oncol; 1998 Dec; 16(12):3858-65. PubMed ID: 9850031
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intrapleural cisplatin and cytarabine in the management of malignant pleural effusions: a Lung Cancer Study Group trial.
    Rusch VW; Figlin R; Godwin D; Piantadosi S
    J Clin Oncol; 1991 Feb; 9(2):313-9. PubMed ID: 1988578
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intrapleural cisplatin and mitomycin for malignant mesothelioma following pleurectomy: pharmacokinetic studies.
    Rusch VW; Niedzwiecki D; Tao Y; Menendez-Botet C; Dnistrian A; Kelsen D; Saltz L; Markman M
    J Clin Oncol; 1992 Jun; 10(6):1001-6. PubMed ID: 1588364
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.